# Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)

> **NCT02731560** · PHASE4 · COMPLETED · sponsor: **Prof. Abid Z. Farooqi** · enrollment: 74 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02731560
- **Lead sponsor:** Prof. Abid Z. Farooqi
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-07
- **Final completion:** 2012-12
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2016-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02731560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02731560, "Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02731560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*